NCT04921878View on ClinicalTrials.gov

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

April 3, 2023

Study Completion Date

April 3, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome injection

Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.

Trial Locations (1)

Unknown

Affiliated Hospital of Hebei University, Baoding

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04921878 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter